linjc16/ctgov huggingface dataset:
The Effect of Chiropractic Manipulation on Spine-related Pain and Balance in Older Adults

Study Overview
=================
Brief Summary
-----------------
The effect of chiropractic manipulation on spine-related pain and balance in older adults.

Detailed Description
-----------------
Chronic pain and risk factors for falls in older adults are significant public health issues. In order to evaluate an appropriate role for chiropractic in managing these problems in the population, this pilot cohort study will take multiple measurements, both self-reported and functional, on a sample of older adults with chronic spine-related pain who are recruited from the local community and receive chiropractic care in the Cleveland Chiropractic College health center over a four-week period.

Official Title
-----------------
The Effect of Chiropractic Manipulation on Spine-related Pain and Balance in Older Adults

Conditions
-----------------
Musculoskeletal Equilibrium, Back Pain

Intervention / Treatment
-----------------
* Procedure: Chiropractic Manipulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 60 or older spine-related pain of >3 months duration (by self-report). Exclusion Criteria: Non-ambulatory chiropractic care or physical therapy within the past month (by self report) contraindications to manipulation, as determined by the clinician through physical exam and x-rays (if indicated) absence of indications for CMT, as determined by the clinician through history, physical exam, orthopedic tests, and static and motion palpation unable to understand English adequately to complete study forms.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Chiropractic Manipulation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Test various recruitment methodologies. |  | Through December 2008 | 
| Describe baseline characteristics of enrolled patients. |  | Through December 2008 | 
| Assess patient outcomes in terms of balance, neck or back pain, and dizziness |  | Through December 2008 |
Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Testing for minimal residual disease in blood samples from patients with acute lymphoblastic leukemia may help doctors plan better treatment. PURPOSE: This research trial studies a genetic test in detecting minimal residual disease in samples from younger patients registered on COG-AALL08B1 trial.

Detailed Description
-----------------
OBJECTIVES: Assess the feasibility of minimal residual disease (MRD) determination in pediatric B-lineage acute lymphoblastic leukemia (ALL) using deep sequencing of the immunoglobulin heavy chain locus. OUTLINE: Archived blood and tumor tissue samples are analyzed for MDR using deep sequencing of immunoglobulin heavy chain locus. MDR quantification results are then compared with the flow cytometry reference methods used in COG studies.

Official Title
-----------------
Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: gene expression analysis
* Other: flow cytometry
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Samples from patients registered on the Children Oncology Group (COG)-AALL08B1 protocol and stored in the Hematopathology Laboratory at the University of Washington Pretreatment and after induction therapy samples PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: gene expression analysis|nan|
|Other: flow cytometry|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity of deep sequencing of the immunoglobulin heavy chain locus in determining MRD in B-lineage ALL |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
B-cell childhood acute lymphoblastic leukemia, untreated childhood acute lymphoblastic leukemia
The Change of the Detrusor Thickness After Hypospadias Repair - Comparison With the Normal Control Group

Study Overview
=================
Brief Summary
-----------------
Even successfully managed hypospadias without any complication, voiding problem could be developed due to the increased urethral resistance. The investigators are trying to analyze the effect of hypospadias operation on voiding function by checking the detrusor thickness and urinary nerve growth factor.

Conditions
-----------------
Hypospadias

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: <Group 1> 6Mo-2Yr old penile hypospadias patients before operation <Group 2> 6Mo-2Yr old male patients without hypospadias <Group 3> penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed <Group 4> 2Yr-5Yr old male patients without hypospadias1. 0-3 year old children without any abnormality of urinary tract Exclusion Criteria: <Group 1, 2, 4> 1. patients with history of urethral operation, febrile urinary tract infection, neurogenic abnormality om operation <Group 3> patients with history of urethral operation other than hypospadias repair, febrile urinary tract infection, neurogenic abnormality patients with development urethra-cutaneous fistula

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 6Mo-2Yr old penile hypospadias patients before operation<br> | |
| 6Mo-2Yr old male patients without hypospadias<br> | |
| penile hypospadias patients under the age of 5 Yr<br>penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed | |
| 2Yr-5Yr old male patients without hypospadias<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detrusor thickness |  | immediate analysis of detrusor thickness at the enrollment time of this study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urinary nerve growth factor level |  | immediate analysis of urinary nerve growth factor level at the enrollment time of this study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypospadias, bladder outlet obstruction, ultrasonography
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

Study Overview
=================
Brief Summary
-----------------
The primary objective of this prospective, observational, post-marketing study is to evaluate the patient characteristics, pre-treatment and treatment duration in Renal Cell Carcinoma (RCC) patients who are candidates for systematic therapy and in whom a decision to treat with Nexavar® has been made under real-life practice settings and approved reimbursement restriction in Taiwan. Therefore, the main objective of the study is to collect data on: Prescription pattern: to determine the factors affecting compliance and duration of treatment with special attention given to education status, demography, disease details, pre-treatment, concomitant medication and other baseline data Nexavar® treatment and efficacy data Adverse events using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Official Title
-----------------
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

Conditions
-----------------
Carcinoma, Renal Cell

Intervention / Treatment
-----------------
* Drug: Sorafenib (Nexavar, BAY43-9006)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by the investigator to prescribe Nexavar® under Taiwan reimbursement guideline Patients must have a life expectancy of at least 8 weeks Exclusion Criteria: Exclusion criteria must follow the approved local product information. Patients were lost to follow-up if no follow-up visit and no final assessment of Nexavar® was documented.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Sorafenib (Nexavar, BAY43-9006)<br>* Patients under daily life treatment according to local drug information<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Safety and Efficacy of treatments and average doses that are used for patients with Renal Cell Carcinoma (collection of number of adverse events) |  | After one year | 
| Evaluation of Safety and Efficacy of treatments and average doses that are used for patients with Renal Cell Carcinoma (collection of changes in tumor status) |  | After one year |
Rate Of Residual Clubfoot Deformity With Correlation To Absence Of Peroneus Tertius Muscle

Study Overview
=================
Brief Summary
-----------------
Rate Of Residual Clubfoot Deformity With Correlation To Absence Of Peroneus Tertius Muscle , A Prospective Study.

Official Title
-----------------
Rate Of Residual Clubfoot Deformity With Correlation To Absence Of Peroneus Tertius Muscle: A Prospective Study

Conditions
-----------------
Clubfoot

Intervention / Treatment
-----------------
* Other: Ultrasound test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients aged 5-17 years , which were treated with the Ponseti technique for Clubfoot in HaEmek medical center, and have sufficient data/follow-up about them in medical records / Exclusion Criteria: patients aged< 5 years Neurological Clubfoot patients with insufficient data in medical records clubfoot caused by arthrogryposis , connective tissue diseases and congenital fibular hemimelia

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Ultrasound test|patients need to undergo an ultrasound test for detecting the presence or abscence of peroneus tertius tendon|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence or Absence of peroneus tertius |  | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peroneus Tertius Muscle
The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population

Study Overview
=================
Brief Summary
-----------------
A technique that has been found to be effective at relieving the physical and psychological symptoms associated with inhibiting emotions and emotional thoughts is written emotional disclosure. The goal of this study is to evaluate the effectiveness of written emotional disclosure on the remediation of eating disorder behaviour, cognitions, and management of emotions.

Detailed Description
-----------------
New Partial program participants complete a packet of questionnaires during their initial appointment, which will be used as baseline levels of eating disorder symptoms and psychological health. Participants will complete the writing as part of their eating disorder therapy. The writing will be completed individually. The writing will consist of continuous writing for fifteen minutes on three consecutive days. The experimental group will write about traumatic or stressful experiences, while the control group will objectively describe events. A post-writing packet of questionnaires will be completed one week after completing the writing. A follow-up evaluation will occur four-weeks after completion of the post-writing packet and will include completing a packet of questionnaires and debriefing.

Official Title
-----------------
Study of the Efficacy of Written Emotional Disclosure on Eating Disorder Pathology

Conditions
-----------------
Anorexia Nervosa, Bulimia Nervosa, Eating Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to sign consent form Exclusion Criteria: Unwilling to sign consent form

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1 Disclosure<br>Traumatic writing prompts provided. Participant is assigned a potential stress-producing topic for written disclosure. | |
| 2 control<br>Received nontraumatic writing prompts. Participant assigned a non-stressful writing condition | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Testing and behavioral changes |  | 6-weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anorexia, bulimia, eating disorder not otherwise specified
HUNgarian COronaVirus Disease-19 Epidemiological Research

Study Overview
=================
Brief Summary
-----------------
Hungarian CoronaVirus disease-19 Epidemiological Research

Detailed Description
-----------------
The planned large-scale, cross-sectional, representative population screening can show the prevalence of COVID-19 and the degree of infection and trans-infection in Hungary after more than one month of strict restriction. In addition, it can have an impact on further actions, and we can track the impact of the decisions we make by repeating the screenings.

Official Title
-----------------
Hungarian CoronaVirus Disease-19 Epidemiological Research

Conditions
-----------------
Coronavirus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hungarian male or female patients aged 14 and over who live in private households Inactivated social security number does not infer the exclusion of the study Exclusion Criteria: Patients under the age of 14 Patients living in institutional households

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COVID-19 rate | The rate of the infected patients, asymptomatic carrier and healed patients | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronavirus
Postoperative Analgesia With Local Infiltration After Periacetabular Osteotomy

Study Overview
=================
Brief Summary
-----------------
Pain treatment after periacetabular osteotomy is traditionally based on systemic opioids wich have side effects. The purpose of this study is to evaluate the analgetic effect of wound infiltration with local anaesthesia after periacetabular osteotomy.

Official Title
-----------------
Postoperative Analgesia With Local Infiltration After Periacetabular Osteotomy For The Treatment Of Dysplasia

Conditions
-----------------
Periacetabular Osteotomy, Pain

Intervention / Treatment
-----------------
* Drug: Ropivacaine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Periacetabular osteotomy due to traditional dysplasia or retroverted acetabulum Informed consent Exclusion Criteria: Intolerance of local anaesthesia Habitual use of opioids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Ropivacaine<br> | Drug: Ropivacaine<br>* Approved by the Danish Medicines Agency<br>|
| Placebo Comparator: Saline<br> | Drug: Placebo<br>* Saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Consumption of rescue analgetics |  | Assesment of opioid rescue analgetics every 24 hours for 14 days postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain |  | Assessment of pain four times every day for five days postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anesthetics, Local infiltration, Periacetabular osteotomy
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

Study Overview
=================
Brief Summary
-----------------
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS). This study evaluates the effect on MRI lesions parameters, the safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis.

Official Title
-----------------
An International, Double-blind, Randomised, Placebo-controlled Phase IIb Trial to Assess the Efficacy, Safety, and Pharmacokinetics of GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis, Relapsing-Remitting

Intervention / Treatment
-----------------
* Drug: GNbAC1
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: For male or female with reproductive potential, use of reliable means of contraception; RRMS according to the 2010 revised McDonald criteria; Disease activity characterised by at least one documented relapse within the last 12 months and /or at least one Gd-enhancing T1 lesion at selection or evidenced within the last 3 months; EDSS score < 6.0. Main Exclusion Criteria: Patients suffering from Secondary Progressive MS and Primary Progressive MS at screening; Pregnant and nursing women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dose 1 GNbAC1<br>Monthly IV repeated dose | Drug: GNbAC1<br>* Monthly IV repeated dose<br>|
| Experimental: Dose 2 GNbAC1<br>Monthly IV repeated dose | Drug: GNbAC1<br>* Monthly IV repeated dose<br>|
| Experimental: Dose 3 GNbAC1<br>Monthly IV repeated dose | Drug: GNbAC1<br>* Monthly IV repeated dose<br>|
| Placebo Comparator: Placebo<br>Monthly IV repeated dose | Drug: Placebo<br>* Monthly IV repeated dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cumulative number of Gd-enhancing T1 lesions in brain MRI |  | Week 12 to 24 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Sclerosis, Multiple Sclerosis Relapsing-Remitting, GNbAC1, MRI, Monoclonal antibody, Multiple Sclerosis associated retrovirus MSRV, MS, RRMS, HERV-W, Temelimab
Cortical Reorganisation in Patients With Primary Headache Disorders

Study Overview
=================
Brief Summary
-----------------
Primary headache disorders are now accepted as physiological diseases, and advanced imaging-techniques have demonstrated a migraine generator in the brain stem and increased stimulus sensitivity in these patients. The underlying neuronal dysfunctions remain to to clarified and the existing neurophysiological methods have not yet been useful. More sensitive and reliable methods are therefore highly needed. The aims of the study are therefore to develop a sensitive and reliable method to demonstrate a cortical reorganisation and expansion of pain sensitive cortical areas in patients with migraine or tension-type headache.

Official Title
-----------------
Cortical Reorganisation in Patients With Primary Headache Disorders

Conditions
-----------------
Migraine Without Aura, Chronic Tension-Type Headache

Intervention / Treatment
-----------------
* Device: EEC-techniques


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis og migraine without aura or chronic tension-type headache Exclusion Criteria: serious somatic or psychiatric diseases including depression overuse of analgesics regular intake of opiates or benzodiazepines intake of prophylactic headache medication pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: EEC-techniques|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |